Thiogenesis Therapeutics Corp

TSXV:TTICanadaView on OTC Pink - Current Information

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the obstacles facing thiol-based drugs, their short half-life, gastrointestinal (GI) side effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for MELAS, Leigh syndrome, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).

Contact Information

Headquarters

4 King Street West, Suite 401Toronto, ON, Canada M5H 1B6

Phone

647-846-7766

Fax

---

Executives

Independent Chairman of the Board

Christopher Starr

Chief Executive Officer, Director

Patrice Rioux

Chief Financial Officer, Secretary, Director

Brook Riggins

Independent Director

W. Hogan Mullally

Independent Director

Kim Tsuchimoto